WeVote
Log In

Bill

Bill

H 4262

Gene Therapies

2025-2026 Regular Session Introduced by Thomas Beach and 19 co-sponsors

South Carolina bill addressing gene therapy regulation and oversight through medical affairs committee review; details on specific provisions unclear from current information.

Member(s) request name added as sponsor: Huff
0
WeVote Research Nonpartisan
Bill Summary · H 4262

Legislative bill overview

H 4262 appears to be a South Carolina bill regarding gene therapies, though specific provisions are not detailed in the available information. The bill was introduced in March 2025 and has been recommitted to the Committee on Medical, Military, Public and Municipal Affairs, suggesting it addresses healthcare regulation and policy matters.

Why is this important

Gene therapy regulation affects patient access to cutting-edge medical treatments, insurance coverage decisions, and how quickly new therapeutic options reach patients. South Carolina's approach to regulating these emerging treatments could influence healthcare costs, treatment availability, and the state's competitiveness in medical innovation.

Potential points of contention

  • Treatment access vs. safety oversight: Balancing rapid approval pathways for gene therapies against ensuring adequate safety testing and long-term efficacy data
  • Insurance coverage and cost: Whether gene therapies will be covered by insurance and how costs are managed, potentially affecting equity in treatment access
  • Regulatory clarity: Defining state versus federal regulatory authority, as gene therapies are primarily FDA-regulated

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.